my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-31-2010: IBA (Ion Beam Applications S.A.) announced that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular imaging compound in development for the detection of Alzheimer’s Disease pathology. The agreement reinforces the companies’ commitment to developing solutions for the early diagnosis and treatment of life threatening diseases.
Under the terms of the agreement, IBA will manufacture and supply Bayer and their trial partners with doses of the compound FLORBETABEN for clinical trials. IBA will develop a large-scale manufacturing process on Synthera®, its proprietary, multi-purpose automated synthesizer, and upgrade its positron emission tomography (PET) manufacturing network in order to ensure availability of the compound for the clinical trials.
Under the terms of the agreement IBA will receive several million Euros (single-digit) of milestone payments and fees depending on the amount of required doses for the clinical trials.
FLORBETABEN is a PET tracer in-licensed by Bayer, undergoing clinical development for potential use in diagnostic imaging of beta-amyloid deposits in the brain, a hallmark of Alzheimer’s Disease.
Watchlist
This is where you can add this news to your personal favourites
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
IBA and Bayer Schering Pharma Sign Clinical Trial Supply Agreement for Alzheimer’s Disease Tracer
IBA (Ion Beam Applications S.A.) announced that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular imaging compound in development for the detection of Alzheimer’s Di ... more
WILEX AG and IBA (Ion Beam Applications SA) announced that the final results of the pivotal phase III registration trial REDECT have been received. The results of the study demonstrate that PET/CT with REDECTANE(R) lead to a significantly improved diagnosis in comparison to CT alone. The a ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
